Analysts: Sarepta’s Competitor Eliminated and 3 Other Research Notes to Browse

| + More Articles
  • Like on Facebook
  • Share on Google+
  • Share on LinkedIn

Sarepta (NASDAQ:SRPT): RW Baird says that the elimination of Prosensa (NASDAQ:RNA) as a potential competitor more than offsets any increase in risk for Sarepta following the failed Phase 3 trial for drisapersen. Baird said it has increased bullishness on Sarepta following today’s news and keeps an Outperform rating on the stock.


More Articles About:

To contact the reporter on this story: To contact the editor responsible for this story:

Yahoo Finance, Harvard Business Review, Market Watch, The Wall St. Journal, Financial Times, CNN Money, Fox Business